Highest-materiality recent filing
Guardian Pharmacy Q1 revenue $336.6M (+2% YoY); raises FY Adjusted EBITDA guidance to $123-127M
Revenue $336.6M (+2% YoY); residents served 207K (+10% YoY). Net income $13.5M vs $9.3M.
Guardian Pharmacy completes $31/share synthetic secondary; loses controlled company status
Company sold 1,020,000 new shares at $31 in public offering; used proceeds to buy 1,020,000 shares from holders, cancelling them; no net share change.
Q4 diluted EPS $0.33, adjusted EPS $0.37; full-year diluted EPS $0.78, adjusted EPS $1.07.
Guardian reiterates 2025 guidance, provides 2026 outlook with ~11% adj. EBITDA growth
Reaffirmed 2025 revenue $1.43B-$1.45B and adjusted EBITDA $104M-$106M.
Guardian Pharmacy Q3 revenue up 20% YoY to $377.4M; raises full-year revenue and EBITDA guidance
Revenue $377.4M (+20% YoY); residents served ~204,000 (+13% YoY).
Guardian Pharmacy extends lock-up on ~93% of pre-IPO shares through June 2026
New lock-up agreements cover ~93% of shares held by founders, executives, and pre-IPO holders, extending restrictions from Oct 19, 2025 to June 30, 2026.
Guardian Pharmacy Q2 revenue up 15%, raises FY guidance; Adj EBITDA $25M
Revenue $344.3M, +15% YoY; resident count >195,000 (+12% YoY).
Guardian Pharmacy to buy up to 1.46M shares from holders in synthetic secondary
Agreed to purchase up to 1,457,365 shares of Class A common stock from certain holders.
Revenue $329.3M (+20% YoY); resident count 189K (+15% YoY) driven by organic growth and acquisitions.
Guardian Pharmacy Q4 revenue up 20% to $338.6M; FY net loss $71M on IPO charges
Q4 revenue $338.6M (+20% YoY); resident count 186,000 (+14% YoY).
Q4 2024 revenue ~$338.6M, +20.5% YoY; net income $10.1-11.1M; adjusted EBITDA ~$25.9M, +30.3% YoY.
Guardian Pharmacy Q3 revenue $314M (+20% YoY); Adj. EBITDA $23M (+20%); guides FY24
Revenue of $314.4M (+20% YoY) driven by organic growth and Heartland Pharmacy acquisition.
Guardian Pharmacy Services closes IPO of 9.2M shares; adopts new governance structure
Closed IPO on Sept 27, 2024; sold 8M Class A shares; underwriters exercised option for 1.2M additional shares.
On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.
On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.
On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.
On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.
On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.
On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.
Max materiality 0.85 · Median 0.65 · Most common event earnings